LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Silver Nanoparticles Targets Tumors

By LabMedica International staff writers
Posted on 17 Jun 2014
Image: Prostate cancer cells were targeted by two separate silver nanoparticles (red and green), while the cell nucleus was labeled in blue using Hoescht dye (Photo courtesy of UCSB – University of California, Santa Barbara).
Image: Prostate cancer cells were targeted by two separate silver nanoparticles (red and green), while the cell nucleus was labeled in blue using Hoescht dye (Photo courtesy of UCSB – University of California, Santa Barbara).
Scientists have devised a nanoparticle that has a couple of unique, and key, characteristics. Spherical in shape and made up of silver, it is encased in a shell coated with a peptide that enables it to target tumor cells. Moreover, the shell is etchable, therefore, those nanoparticles that do not hit their target can be broken down and eliminated.

The research findings were published June 8, 2014, in the journal Nature Materials. The core of the nanoparticle employs a feature known as plasmonics. In plasmonics, nanostructured metals such as silver and gold resonate in light and concentrate the electromagnetic field near the surface. In this manner, fluorescent dyes are enhanced, appearing about 10 times brighter than their natural state when no metal is present. When the core is etched, the enhancement retreats and the particle becomes dim.

University of California-Santa Barbara’s (UCSB; USA) Ruoslahti Research Laboratory also developed a simple etching technique using biocompatible chemicals to quickly disassemble and take away the silver nanoparticles outside living cells. This method leaves only the intact nanoparticles for imaging or quantification, thus revealing which cells have been targeted and how much each cell internalized.

“The disassembly is an interesting concept for creating drugs that respond to a certain stimulus,” said Gary Braun, a postdoctoral associate in the Ruoslahti Lab in the department of molecular, cellular and developmental biology (MCDB) and at Sanford-Burnham Medical Research Institute. “It also minimizes the off-target toxicity by breaking down the excess nanoparticles so they can then be cleared through the kidneys.”

This method for removing nanoparticles unable to penetrate target cells is unique. “By focusing on the nanoparticles that actually got into cells,” Dr. Braun said, “we can then understand which cells were targeted and study the tissue transport pathways in more detail.”

Various agents are able to pass through the cell membrane by themselves, but many drugs, particularly RNA and DNA genetic drugs, are charged molecules that are stopped by the membrane. These drugs must be taken in through endocytosis, the process by which cells absorb molecules by surrounding them. “This typically requires a nanoparticle carrier to protect the drug and carry it into the cell,” Dr. Braun said. “And that’s what we measured: the internalization of a carrier via endocytosis.”

Because the nanoparticle has a core shell structure, the researchers can vary its exterior coating and compare the efficiency of tumor targeting and internalization. Switching out the surface agent enables the targeting of different diseases—or organisms in the case of bacteria—through the use of different target receptors. According to Dr. Braun, this should become a strategy to optimize drug delivery where the core is a drug-containing vehicle.

“These new nanoparticles have some remarkable properties that have already proven useful as a tool in our work that relates to targeted drug delivery into tumors,” said Erkki Ruoslahti, adjunct distinguished professor in UCSB’s Center for Nanomedicine and MCDB department and at Sanford-Burnham Medical Research Institute. “They also have potential applications in combating infections. Dangerous infections caused by bacteria that are resistant to all antibiotics are getting more common, and new approaches to deal with this problem are desperately needed. Silver is a locally used antibacterial agent and our targeting technology may make it possible to use silver nanoparticles in treating infections anywhere in the body.”

Related Links:

University of California-Santa Barbara


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Human Estradiol Assay
Human Estradiol CLIA Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more